Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04755283
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-10
First Post:
2021-02-11
Brief Title:
Safety and Tolerability of Abelacimab MAA868 vs Rivaroxaban in Patients With Atrial Fibrillation
Sponsor:
Anthos Therapeutics Inc
Organization:
Anthos Therapeutics Inc
Study Overview
Official Title:
A Multicenter RandomiZed Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab MAA868 Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation AZALEA
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AZALEA-TIMI 71
Brief Summary:
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation AF at moderate-to-high risk of stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-004507-13 | EUDRACT_NUMBER | None | None |